United Therapeutics (NASDAQ:UTHR) CEO Sells $5,091,905.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the firm’s stock in a transaction that occurred on Monday, July 13th. The shares were sold at an average price of $535.99, for a total value of $5,091,905.00. Following the completion of the sale, the chief executive officer directly owned 40,513 shares of the company’s stock, valued at approximately $21,714,562.87. The trade was a 19.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

United Therapeutics Stock Performance

Shares of NASDAQ UTHR traded down $8.91 during trading hours on Tuesday, reaching $526.66. 372,599 shares of the stock were exchanged, compared to its average volume of 490,527. The stock’s fifty day simple moving average is $555.98 and its 200 day simple moving average is $529.73. The firm has a market capitalization of $22.36 billion, a price-to-earnings ratio of 19.44, a P/E/G ratio of 1.80 and a beta of 0.58. United Therapeutics Corporation has a 52 week low of $272.12 and a 52 week high of $609.35.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing the consensus estimate of $7.00 by ($1.18). The company had revenue of $781.50 million during the quarter, compared to the consensus estimate of $797.40 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The company’s quarterly revenue was down 1.6% on a year-over-year basis. During the same quarter last year, the firm posted $6.63 earnings per share. Research analysts predict that United Therapeutics Corporation will post 26.63 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently issued reports on UTHR shares. Raymond James Financial initiated coverage on United Therapeutics in a report on Friday, April 10th. They set an “outperform” rating and a $700.00 target price on the stock. Wells Fargo & Company raised United Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their price target for the company from $575.00 to $735.00 in a research note on Thursday, May 7th. HC Wainwright upped their price objective on shares of United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a research report on Tuesday, March 31st. TD Cowen reiterated a “buy” rating on shares of United Therapeutics in a research note on Thursday, May 21st. Finally, Bank of America decreased their target price on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a report on Friday. Ten research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $644.82.

Hedge Funds Weigh In On United Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of UTHR. Handelsbanken Fonder AB raised its holdings in shares of United Therapeutics by 4.1% during the 2nd quarter. Handelsbanken Fonder AB now owns 13,120 shares of the biotechnology company’s stock worth $7,109,000 after buying an additional 520 shares in the last quarter. PensionDanmark Pensionsforsikringsaktieselskab boosted its stake in United Therapeutics by 7.4% in the second quarter. PensionDanmark Pensionsforsikringsaktieselskab now owns 11,058 shares of the biotechnology company’s stock valued at $5,992,000 after buying an additional 760 shares in the last quarter. Assenagon Asset Management S.A. boosted its stake in United Therapeutics by 79.2% in the second quarter. Assenagon Asset Management S.A. now owns 84,538 shares of the biotechnology company’s stock valued at $45,805,000 after buying an additional 37,355 shares in the last quarter. GAMMA Investing LLC grew its position in United Therapeutics by 10.3% in the second quarter. GAMMA Investing LLC now owns 1,769 shares of the biotechnology company’s stock valued at $958,000 after acquiring an additional 165 shares during the last quarter. Finally, Versant Capital Management Inc grew its position in United Therapeutics by 93.6% in the second quarter. Versant Capital Management Inc now owns 182 shares of the biotechnology company’s stock valued at $99,000 after acquiring an additional 88 shares during the last quarter. Institutional investors own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.